⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2024Open Access

Supplementary Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer

Jesse Boumelha Andrea de Castro Nourdine Bah Hongui Cha Sophie de Carné Trécesson Sareena Rana Mona Tomaschko Panayiotis Anastasiou Edurne Mugarza Christopher Moore Robert Goldstone Philip East Kevin Litchfield Se‐Hoon Lee Míriam Molina‐Arcas Julian Downward

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 2. KRAS-driven inhibition of tumor-intrinsic IFN signaling promotes immune evasion

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Boumelha et al. (2024) studied this question.

synapsesocial.com/papers/68e60477b6db6435875984c6 https://doi.org/10.1158/0008-5472.26302463.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer2024
2Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer2024
3Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer2024
4Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer2024
5Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer2024